Pfizer's BRAFTOVI Combo Nearly Doubles PFS In BRAF V600E Metastatic Colorectal Cancer
31/5 14:40
(RTTNews) - Pfizer Inc. (PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 BREAKWATER trial. This randomized cohort evaluated BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and...